Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

C-reactive Protein as a Diagnostic and Prognostic Factor of Endometrial Cancer

Version 1 : Received: 18 July 2020 / Approved: 19 July 2020 / Online: 19 July 2020 (21:13:19 CEST)

How to cite: Socha, M.W.; Malinowski, B.; Wartęga, M.; Puk, O.; Wolski, B.; Wiciński, M. C-reactive Protein as a Diagnostic and Prognostic Factor of Endometrial Cancer. Preprints 2020, 2020070448 (doi: 10.20944/preprints202007.0448.v1). Socha, M.W.; Malinowski, B.; Wartęga, M.; Puk, O.; Wolski, B.; Wiciński, M. C-reactive Protein as a Diagnostic and Prognostic Factor of Endometrial Cancer. Preprints 2020, 2020070448 (doi: 10.20944/preprints202007.0448.v1).

Abstract

Endometrial Cancer (EC) is the sixth most commonly occurring cancer in women with 380 000 cases in 2018. Sadly, EC morbidity and mortality are continuously increasing, therefore the medical society have a substantial need for an accurate and inexpensive diagnostic test for EC early detection and a prognostic tool for treatment planning and evaluation. Considering experience with different types of cancers C-reactive protein (CRP) appears to be a promising diagnostic and prognostic factor. Aiming to investigate its potential and in view of EC authors, this paper reviewed the following databases for metanalysis, randomized controlled trials and review articles published up to June 2020: Pubmed, Scopus, Google scholar and ClinicalKey. Studies indicate CRP >3.33 mg/l correlate with EC incidence with HR = 2.29 (p<0.05). Moreover, High-sensitivity CRP assay allows to detect CRP in very low concentrations and distinguish patients with endometriosis, soft tissue sarcomas and possibly EC. Preoperational and postoperational CRP, as well as its dynamic change are independent prognostic factors for EC and are more reliable if analyzed together. However, CRP-to-albumin ratio as well as Glasgow Prognostic Scale have greater prognostic value that CRP alone. Additionally, CRP is possibly a mediator of carcinogenesis and cancer progression through activation of inter alia FcgRs/MAPK/ERK, FcgRs/IL-6/AKT/STAT3 and FcgRs/NF-κB/NLRP3 pathways.

Subject Areas

C-reactive protein; hs-CRP; albumins; Glasgow Prognostic Score; Endometrial Cancer; CRP to albumin ratio; CRP; Cancer; Inflammation

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.